{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:35:13Z","timestamp":1769837713781,"version":"3.49.0"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"3","funder":[{"DOI":"10.13039\/501100002261","name":"Russian Research Foundation","doi-asserted-by":"crossref","award":["20-75-10158"],"award-info":[{"award-number":["20-75-10158"]}],"id":[{"id":"10.13039\/501100002261","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This review aimed to summarize the pharmacogenetic studies of the most commonly used drugs in the chemotherapy of gastrointestinal (GI) tumors: oxaliplatin, irinotecan, and fluoropyrimidines. So far, it has not been possible to develop an effective genotype-based approach for oxaliplatin. More and more evidence is emerging in favor of the fact that the choice of a dose of fluorouracil based on pharmacogenetic testing according to\n                    <jats:italic>DPYD*2A<\/jats:italic>\n                    , can be not\u00a0only effective but also cost-effective. Additional, well-planned trials of the\n                    <jats:italic>UGT1A1<\/jats:italic>\n                    genotype-based approach to irinotecan therapy are predicted to reduce adverse drug events in people with the\n                    <jats:italic>UGT1A1*28\/*28<\/jats:italic>\n                    genotypes and improve treatment efficacy in the rest of the patients, which might be cost-effective.\n                  <\/jats:p>","DOI":"10.1515\/dmpt-2021-0162","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T21:48:35Z","timestamp":1663105715000},"page":"223-228","source":"Crossref","is-referenced-by-count":7,"title":["Genotype-based chemotherapy for patients with gastrointestinal tumors: focus on oxaliplatin, irinotecan, and fluoropyrimidines"],"prefix":"10.1515","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-7367","authenticated-orcid":false,"given":"Denis S.","family":"Fedorinov","sequence":"first","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare , Moscow , Russian Federation"},{"name":"City Clinical Cancer Hospital , Moscow , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vladimir K.","family":"Lyadov","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare , Moscow , Russian Federation"},{"name":"City Clinical Cancer Hospital , Moscow , Russian Federation"},{"name":"Novokuznetsk State Institute of Postgraduate Medical Education , Novokuznetsk , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dmitriy A.","family":"Sychev","sequence":"additional","affiliation":[{"name":"Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare , Moscow , Russian Federation"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,11,30]]},"reference":[{"key":"2025121207241447860_j_dmpt-2021-0162_ref_001","unstructured":"Cancer stat facts [Online]. Available from: https:\/\/seer.cancer.gov\/statfacts."},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_002","doi-asserted-by":"crossref","unstructured":"Onakpoya, IJ, Heneghan, CJ, Aronson, JK. Worldwide withdrawal of medicinal products because of adverse drug reactions: a systematic review and analysis. Crit Rev Toxicol 2016;46:477\u201389. https:\/\/doi.org\/10.3109\/10408444.2016.1149452.","DOI":"10.3109\/10408444.2016.1149452"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_003","doi-asserted-by":"crossref","unstructured":"Meulendijks, D, Henricks, LM, Sonke, GS, Deenen, MJ, Froehlich, TK, Amstutz, U, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015;16:1639\u201350. https:\/\/doi.org\/10.1016\/s1470-2045(15)00286-7.","DOI":"10.1016\/S1470-2045(15)00286-7"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_004","doi-asserted-by":"crossref","unstructured":"Shahnam, A, Ridha, Z, Wiese, MD, Kichenadasse, G, Sorich, MJ. Pharmacogenetic and ethnicity influence on oxaliplatin therapy for colorectal cancer: a meta-analysis. Pharmacogenomics 2016;17:1725\u201332. https:\/\/doi.org\/10.2217\/pgs-2016-0102.","DOI":"10.2217\/pgs-2016-0102"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_005","doi-asserted-by":"crossref","unstructured":"Dias, MM, Pignon, J-P, Karapetis, CS, Boige, V, Glimelius, B, Kweekel, DM, et al.. The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. Pharmacogenomics J 2014;14:424\u201331. https:\/\/doi.org\/10.1038\/tpj.2014.16.","DOI":"10.1038\/tpj.2014.16"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_006","unstructured":"Graham, MA, Lockwood, GF, Greenslade, D, Brienza, S, Bayssas, M, Gamelin, E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res Off J Am Assoc Cancer Res 2000;6:1205\u201318."},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_007","doi-asserted-by":"crossref","unstructured":"Hoeijmakers, JH. Nucleotide excision repair. II: from yeast to mammals. Trends Genet 1993;9:211\u20137. https:\/\/doi.org\/10.1016\/0168-9525(93)90121-w.","DOI":"10.1016\/0168-9525(93)90121-W"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_008","doi-asserted-by":"crossref","unstructured":"Abad, A, Mart\u00ednez-Balibrea, E, Vi\u00e9itez, JM, Alonso-Ordu\u00f1a, V, Garc\u00eda Alfonso, P, Manzano, JL, et al.. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. Ann Oncol 2018;29:439\u201344. https:\/\/doi.org\/10.1093\/annonc\/mdx737.","DOI":"10.1093\/annonc\/mdx737"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_009","doi-asserted-by":"crossref","unstructured":"Catenacci, DVT, Chase, L, Lomnicki, S, Karrison, T, de Wilton Marsh, R, Rampurwala, MM, et al.. Evaluation of the association of perioperative UGT1A1 genotype-dosed gFOLFIRINOX with margin-negative resection rates and pathologic response grades among patients with locally advanced gastroesophageal adenocarcinoma: a phase 2 clinical trial. JAMA Netw Open 2020;3:e1921290. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.21290.","DOI":"10.1001\/jamanetworkopen.2019.21290"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_010","doi-asserted-by":"crossref","unstructured":"McWilliams, RR, Foster, NR, Mahoney, MR, Smyrk, TC, Murray, JA, Ames, MM, et al.. North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer 2017;123:3494\u2013501. https:\/\/doi.org\/10.1002\/cncr.30766.","DOI":"10.1002\/cncr.30766"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_011","doi-asserted-by":"crossref","unstructured":"Maekawa, K, Harakawa, N, Yoshimura, T, Kim, S-R, Fujimura, Y, Aohara, F, et al.. CYP3A4 * 16 and CYP3A4 * 18 alleles found in East Asians exhibit differential catalytic activities for seven CYP3A4 substrate drugs. Drug Metab Dispos 2010;38:2100\u20134. https:\/\/doi.org\/10.1124\/dmd.110.034140.","DOI":"10.1124\/dmd.110.034140"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_012","doi-asserted-by":"crossref","unstructured":"Hahn, RZ, Antunes, MV, Verza, SG, Perassolo, MS, Suyenaga, ES, Schwartsmann, G, et al.. Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. Curr Med Chem 2019;26:2085\u2013107. https:\/\/doi.org\/10.2174\/0929867325666180622141101.","DOI":"10.2174\/0929867325666180622141101"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_013","doi-asserted-by":"crossref","unstructured":"L\u00e9vesque, E, B\u00e9langer, A-S, Harvey, M, Couture, F, Jonker, D, Innocenti, F, et al.. Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil\/irinotecan-based regimens. J Pharmacol Exp Therapeut 2013;345:95\u2013101.","DOI":"10.1124\/jpet.112.202242"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_014","doi-asserted-by":"crossref","unstructured":"O\u2019Dwyer, PJ, Catalano, RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 2006;24:4534\u20138.","DOI":"10.1200\/JCO.2006.07.3031"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_015","doi-asserted-by":"crossref","unstructured":"Toffoli, G, Cecchin, E, Corona, G, Russo, A, Buonadonna, A, D\u2019Andrea, M, et al.. The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol 2006;24:3061\u20138. https:\/\/doi.org\/10.1200\/jco.2005.05.5400.","DOI":"10.1200\/JCO.2005.05.5400"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_016","doi-asserted-by":"crossref","unstructured":"P\u00e1ez, D, Tobe\u00f1a, M, Fern\u00e1ndez-Plana, J, Sebio, A, Virgili, AC, Cirera, L, et al.. Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype. Br J Cancer 2019;120:190\u20135.","DOI":"10.1038\/s41416-018-0348-7"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_017","doi-asserted-by":"crossref","unstructured":"Toffoli, G, Cecchin, E, Gasparini, G, D\u2019Andrea, M, Azzarello, G, Basso, U, et al.. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil\/leucovorin in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:866\u201371. https:\/\/doi.org\/10.1200\/jco.2009.23.6125.","DOI":"10.1200\/JCO.2009.23.6125"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_018","doi-asserted-by":"crossref","unstructured":"Kroetz, DL. Role for drug transporters beyond tumor resistance: hepatic functional imaging and genotyping of multidrug resistance transporters for the prediction of irinotecan toxicity. J Clin Oncol Off J Am Soc Clin Oncol 2006;24:4225\u20137. https:\/\/doi.org\/10.1200\/jco.2006.07.2355.","DOI":"10.1200\/JCO.2006.07.2355"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_019","doi-asserted-by":"crossref","unstructured":"de Man, FM, Goey, AKL, van Schaik, RHN, Mathijssen, RHJ, Bins, S. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018;57:1229\u201354. https:\/\/doi.org\/10.1007\/s40262-018-0644-7.","DOI":"10.1007\/s40262-018-0644-7"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_020","doi-asserted-by":"crossref","unstructured":"Hoff, PM, Ansari, R, Batist, G, Cox, J, Kocha, W, Kuperminc, M, et al.. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol 2001;19:2282\u201392. https:\/\/doi.org\/10.1200\/jco.2001.19.8.2282.","DOI":"10.1200\/JCO.2001.19.8.2282"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_021","unstructured":"van Kuilenburg, ABP, Meinsma, R, Zonnenberg, BA, Zoetekouw, L, Baas, F, Matsuda, K, et al.. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res Off J Am Assoc Cancer Res 2003;9:4363\u20137."},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_022","doi-asserted-by":"crossref","unstructured":"Van Kuilenburg, AB, van Lenthe, H, Blom, MJ, Mul, EP, Van Gennip, AH. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: major implications for the detection of partly deficient patients. Br J Cancer 1999;79:620\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6690097.","DOI":"10.1038\/sj.bjc.6690097"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_023","doi-asserted-by":"crossref","unstructured":"Swen, JJ, Nijenhuis, M, de Boer, A, Grandia, L, Maitland-van der Zee, AH, Mulder, H, et al.. Pharmacogenetics: from bench to byte--an update of guidelines. Clin Pharmacol Ther 2011;89:662\u201373. https:\/\/doi.org\/10.1038\/clpt.2011.34.","DOI":"10.1038\/clpt.2011.34"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_024","doi-asserted-by":"crossref","unstructured":"`van Kuilenburg, ABP. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939\u201350. https:\/\/doi.org\/10.1016\/j.ejca.2003.12.004.","DOI":"10.1016\/j.ejca.2003.12.004"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_025","doi-asserted-by":"crossref","unstructured":"Deenen, MJ, Meulendijks, D, Cats, A, Sechterberger, MK, Severens, JL, Boot, H, et al.. Upfront genotyping of DPYD * 2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 2016;34:227\u201334. https:\/\/doi.org\/10.1200\/jco.2015.63.1325.","DOI":"10.1200\/JCO.2015.63.1325"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_026","doi-asserted-by":"crossref","unstructured":"Henricks, LM, van Merendonk, LN, Meulendijks, D, Deenen, MJ, Beijnen, JH, de Boer, A, et al.. Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD *2A variant: a matched pair analysis: matched pair analysis of DPYD *2A carriers. Int J Cancer 2019;144:2347\u201354. https:\/\/doi.org\/10.1002\/ijc.32022.","DOI":"10.1002\/ijc.32022"},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_027","unstructured":"Kawakami, K, Salonga, D, Park, JM, Danenberg, KD, Uetake, H, Brabender, J, et al.. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin Cancer Res Off J Am Assoc Cancer Res 2001;7:4096\u2013101."},{"key":"2025121207241447860_j_dmpt-2021-0162_ref_028","doi-asserted-by":"crossref","unstructured":"Soo, RA, Syn, N, Lee, S-C, Wang, L, Lim, X-Y, Loh, M, et al.. Pharmacogenetics-guided phase I study of capecitabine on an intermittent schedule in patients with advanced or metastatic solid tumours. Sci Rep 2016;6:27826. https:\/\/doi.org\/10.1038\/srep27826.","DOI":"10.1038\/srep27826"}],"container-title":["Drug Metabolism and Personalized Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0162\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0162\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:23:09Z","timestamp":1765527789000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dmpt-2021-0162\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,30]]},"references-count":28,"aliases":["10.1515\/dmdi-2021-0162"],"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,11,30]]},"published-print":{"date-parts":[[2022,9,13]]}},"alternative-id":["10.1515\/dmpt-2021-0162"],"URL":"https:\/\/doi.org\/10.1515\/dmpt-2021-0162","relation":{},"ISSN":["2363-8915"],"issn-type":[{"value":"2363-8915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,30]]}}}